Access to European Union law
<a href="https://eur-lex.europa.eu/content/help/eurlex-content/experimental-features.html" target="_blank">More about the experimental features corner</a>
Choose the experimental features you want to try
EUR-Lex
Access to European Union law

This document is an excerpt from the EUR-Lex website

You are here
Use quotation marks to search for an "exact phrase". Append an asterisk (*) to a search term to find variations of it (transp*, 32019R*). Use a question mark (?) instead of a single character in your search term to find variations of it (ca?e finds case, cane, care).
Search tips
Need more search options? Use the Advanced search

Document 62022TN0412

Case T-412/22: Action brought on 4 July 2022 — PAN Europe v Commission

OJ C 326, 29.8.2022, pp. 22–23 (BG, ES, CS, DA, DE, ET, EL, EN, FR, GA, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)

29.8.2022   

EN

Official Journal of the European Union

C 326/22

Action brought on 4 July 2022 — PAN Europe v Commission

(Case T-412/22)

(2022/C 326/30)

Language of the case: English

Parties

Applicant: Pesticide Action Network Europe (PAN Europe) (Brussels, Belgium) (represented by: A. Bailleux, lawyer)

Defendant: European Commission

Form of order sought

The applicant claims that the Court should:

—

annul the Commission’s decision, dated 27 April 2022, to reject the applicant’s request for internal review, regarding Commission Implementing Regulation (EU) 2021/2068, (1) insofar as it postpones the expiry of the approval period of dimoxystrobin;

—

order the Commission to bear the costs of the proceedings.

Pleas in law and main arguments

In support of the action, the applicant relies on two pleas in law.

1.

First plea in law, in principal order, alleging that the contested decision must be annulled because it is based on an unlawful interpretation of Article 17 of Regulation (EC) No 1107/2009 of the European Parliament and of the Council of 21 October 2009 (‘the PPP Regulation’). (2)

—

It is argued that the contested decision is based on a reading of Article 17 of the PPP Regulation which is not compatible with:

—

the substantial requirements laid down in Articles 4, 5 and 21 of and point 3.6.5. of Annex II to the PPP Regulation and contained in Articles 9, 11, 168 and 191 TFEU and in Articles 35 and 37 of the Charter of Fundamental Rights of the EU;

—

the expediency requirements contained in Articles 7, 9, 12, 14 and 15 of the PPP Regulation.

2.

Second plea in law, in subsidiary order, alleging that Article 17 of the PPP Regulation must be disapplied, according to Article 277 TFEU, because it is contrary to the precautionary principle, Articles 9, 11, 168 and 191 TFEU, and Articles 35 and 37 of the Charter of Fundamental Rights of the EU.

—

It is argued that, if the Court were to take the view that the contested decision (and the Commission Implementing Regulation) is based on a sound reading of Article 17 of the PPP Regulation, this legislative provision should be set aside for the purpose of the present proceedings, pursuant to Article 277 TFEU, because it would be contrary to the precautionary principle, Articles 9, 11, 168 and 191 TFEU and Articles 35 and 37 of the Charter. Accordingly, Article 17 could not serve as a proper legal justification for the contested decision, which must therefore be annulled.

(1)  Commission Implementing Regulation (EU) 2021/2068 of 25 November 2021 amending Implementing Regulation (EU) No 540/2011 as regards the extension of the approval periods of the active substances benfluralin, dimoxystrobin, fluazinam, flutolanil, mecoprop-P, mepiquat, metiram, oxamyl and pyraclostrobin (OJ 2021 L 421, p. 25).

(2)  Regulation (EC) No 1107/2009 of the European Parliament and of the Council of 21 October 2009 concerning the placing of plant protection products on the market and repealing Council Directives 79/117/EEC and 91/414/EEC (OJ 2009 L 309, p. 1).

Top